Primary Endpoint in POLARIX Trial
Polivy's pivotal phase 3 POLARIX trial measured effectiveness mainly through progression-free survival (PFS), defined as time from randomization to disease progression per Independent Review Committee (IRC) assessment using Lugano criteria or death from any cause.[1][2] This endpoint showed polivy plus R-CHP improved PFS by 27% (HR 0.73; 95% CI 0.57-0.95; p=0.018), with median PFS not reached in the polivy arm versus 34.8 months in the R-CHP control arm after 28.1 months median follow-up.[1]
Secondary Endpoints and Overall Response
Key secondary measures included complete response (CR) rate, assessed via PET-CT scans under Lugano 2014 criteria, where polivy + R-CHP achieved 40.1% CR versus 35.5% for R-CHP.[1][3] Objective response rate (ORR; CR + partial response) was similar at 82.5% versus 82.7%.[1] Minimal residual disease (MRD) negativity via PET and ctDNA added depth to response evaluation.[2]
How Progression Was Assessed
Trials used modified Lugano classification: PET-CT for FDG-avid disease, CT/MRI for non-avid, with bone marrow biopsy only if clinically indicated post-treatment. IRC blinded reviews minimized bias, with sensitivity analyses confirming PFS benefit consistency across subgroups like high-risk IPI scores.[1][4]
Overall Survival and Long-Term Data
Interim overall survival (OS) data were immature, with no significant difference (HR 0.82; 95% CI 0.57-1.17), but trends favored polivy arm.[1] Updated 4-year follow-up showed sustained PFS advantage (HR 0.70).[5] OS remains a key ongoing measure.
Comparison to Earlier Trials
Phase 2 trials like ROMULUS used overall response rate (ORR) and duration of response (DOR) as primary endpoints, with ORR up to 82% in relapsed settings, bridging to phase 3 PFS focus.[6]
[1]: New England Journal of Medicine - Polivy POLARIX Trial (2022)
[2]: FDA Approval Summary for Polivy (2021)
[3]: Lugano Classification (2014)
[4]: European Medicines Agency - Polivy Assessment (2022)
[5]: ASH 2023 Abstract - POLARIX Update
[6]: ClinicalTrials.gov - ROMULUS (NCT02692952)